Evidence map›Paper›PMID 30356307›Full record

ArticlePloS one2018

Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population.

Hari Vishal Lakhani, Tilak Khanal, Alaa Gabi, George Yousef, Mian Bilal Alam, Dana Sharma, Haytham Aljoudi, Nitin Puri, Ellen Thompson, Joseph I Shapiro and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hari Vishal LakhaniDepartment of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Tilak KhanalDepartment of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Alaa GabiDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
George YousefDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Mian Bilal AlamDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Dana SharmaDepartment of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Haytham AljoudiDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Nitin PuriDepartments of Biomedical Sciences, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Ellen ThompsonDivision of Cardiology, Department of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.ORCID 0000-0002-4029-5398
Joseph I ShapiroDepartment of Internal Medicine, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.
Komal SodhiDepartments of Surgery and Biomedical Sciences, Marshall University Joan C Edwards School of Medicine, Huntington, WV, United States of America.ORCID 0000-0002-1179-2985
Marshall University · US

Funding

CORAL: Clinical Coordinating CenterU01HL071556 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COOPER, CHRISTOPHER J · 2004 to 2013
$19.3M
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac DiseasesR01HL109015 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SHAPIRO, JOSEPH ISAAC, XIE, ZIJIAN · 2011 to 2014
$2.2M
Na/K-ATPase Reduction in Renal Disease-Related Cardiac DysfunctionR01HL105649 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI TIAN, JIANG · 2012 to 2016
$1.8M
NHLBI NIH HHS R01 HL105649NHLBI NIH HHS R01 HL109015NHLBI NIH HHS U01 HL071556
6 · The paper itself

Abstract

backgroundMyocardial infarction is the most common cause of heart failure. MI has been intricately linked to ventricular remodeling, subsequently leading to the reduction in the cardiac ejection fraction causing HF. The cumulative line of evidence suggests an important role of several biomarkers in modulating the cardiac vasculature, further contributing towards the progression of post-MI complications. Studies have demonstrated, yet not fully established, that an important biomarker, IL-10, has a causal relationship with MI and associated cardiac dysfunction. HYPOTHESIS: This study aims to establish the role of IL-10 as a prognostic marker for the cardiovascular outcomes and to develop a panel of biomarkers and circulating miRNAs that could potentially result in the early detection of HF resulting from MI, allowing for early intervention strategies. METHODS AND

resultsBlood was withdrawn and echocardiography assessment was performed on a total of 43 patients that were enrolled, within 24 hours of the incidence of MI. Patients were divided in three main groups, based on the ejection fraction measurement from echocardiography: control (n = 14), MI with normal EF (MI+NEF, n = 13) and MI with low EF (MI+LEF, n = 16). Our results showed that TGFβ-1, TNF-α, IL-6 and MMP-9 were upregulated significantly in MI+NEF group and more so in MI+LEF group, as compared to control group (p<0.01). The circulating levels of miR-34a, miR-208b and miR-126 were positively correlated and showed elevated levels in the MI+NEF group, even higher in MI+LEF group, while levels of miR-24 and miR-29a were reduced in MI+NEF, and much lower in MI+LEF, as compared to the control group (p<0.01). Our results also demonstrated a direct correlation of IL-10 with the ejection fraction in patients with MI: IL-10 was elevated in MI+NEF group, however, the levels were significantly low in MI+LEF group suggesting an important role of IL-10 in predicting heart failure. Importantly, our study confirmed the correlation of IL-10 with EF by our follow-up echocardiography assessment that was performed 2 months after the incidence of MI.

conclusionOur results support the clinical application of these serum biomarkers to develop a panel for appropriate prognosis and management of adverse cardiac remodeling and development of heart failure post-myocardial infarction.

Indexed as

AgedBiomarkersEchocardiographyFemaleGene Expression RegulationHeart FailureHumansInterleukin-10MaleMatrix Metalloproteinase 9MicroRNAsMiddle AgedMyocardial InfarctionPrognosisStroke VolumeTransforming Growth Factor betaBiomarkersIL10 protein, humanInterleukin-10Matrix Metalloproteinase 9MicroRNAsMMP9 protein, humanTransforming Growth Factor betaTumor Necrosis Factor-alpha

Identifiers

PMID30356307
PMCPMC6200226
OpenAlexW2898564435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.